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We investigated the immune response against a human immunodeficiency virus type 1 (HIV-1) nef DNA sequence
administered epidermally in mice transgenic for the human major histocompatibility complex (MHC) class I molecule
HLA-A201. Ten potential HLA-A2 binding 9-mer Nef peptides were identified by a computer-based search algorithm. By a cell
surface MHC class I stabilization assay, four peptides were scored as good binders, whereas two peptides bound weakly to
HLA-A2. After DNA immunization, cytotoxic T lymphocyte (CTL) responses were predominantly directed against the Nef
44-52, 81-89, and 85-93 peptides. Interestingly, the 44-52 epitope resides outside the regions of Nef where previously
described CTL epitopes are clustered. Dominance among Nef-derived peptides did not strictly correlate with HLA-A2 binding,
in that only one of the high-affinity binding peptides was targeted in the CTL response. The 44-52, 85-93, and 139-147
peptides also generated specific CTLs in response to peptide immunization. T helper cell proliferation was detected after
stimulation with 20-mer peptides in vitro. Three Nef regions (16-35, 106-125, and 166-185) dominated the T helper cell
proliferation. The implications of these results for the development of DNA-based vaccines against HIV is discussed. © 2000
Academic PressINTRODUCTION
Cytotoxic T lymphocytes (CTLs) recognize viral pep-
tides presented by major histocompatibility complex
(MHC) class I (Pamer and Cresswell, 1998) and have
the capacity to lyse infected cells before the produc-
tion of progeny virions (Yang et al., 1996; Zinkernagel
and Althage, 1977). Several lines of evidence support
a key role for CTLs in the immune control of human
immunodeficiency virus type 1 (HIV-1) infection (re-
viewed in Brander and Walker, 1999). CTLs are tem-
porally associated with the containment of primary
viremia and remain at high frequency for prolonged
periods of time (Borrow et al., 1994; Koup et al., 1994).
Strong evidence comes from the observation that
there is an inverse correlation between the frequency
of specific CTLs and viral RNA load in chronic HIV
infection (Ogg et al., 1998). Furthermore, antibody-
mediated depletion of CD81 T cells in vivo leads to a
dramatic increase in simian immunodeficiency virus
(SIV) viral load in macaques (Jin et al., 1999; Schmitz et
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112al., 1999). The emergence of viral epitope escape
mutants suggests that CTL responses exert a signifi-
cant selection pressure during the course of infection
(Evans et al., 1999; Koenig et al., 1995; Phillips et al.,
1991; Soudeyns et al., 1999). Taken together, these
data strongly indicate an important role for CTLs in the
containment of HIV-1 infection and support the notion
that candidate vaccines should induce strong CTL
responses to be successful.
Accumulating evidence indicates that the regulatory
Nef protein plays a key role in the pathogenesis and
development of AIDS (Peter, 1998). Nef is expressed
early in infection (Kim et al., 1989) and is responsible for
high titer virus replication in vivo (Kestler et al., 1991).
Long-time survivors of HIV infection show a lack of dis-
ease progression, commonly associated with deletions
in the nef gene (Deacon et al., 1995; Kirchhoff et al., 1995)
or defective nef alleles (Mariani et al., 1996). Moreover,
nef was the only gene absolutely necessary to develop
an AIDS-like disease in HIV-1 transgenic mice (Hanna et
al., 1998). The Nef protein acts together with Env and Vpu
proteins to down-regulate cell surface expression of the
major HIV receptor CD4 (Aiken et al., 1994; Chen et al.,
1996). Nef also acts to reduce the levels of MHC class I
at the cell surface (Schwartz et al., 1996), thus preventing





























113HIV-1 NEF T-CELL RESPONSES IN HLA-A2 TRANSGENIC MICEFurthermore, high frequencies of CTLs specific for Nef
have been detected in HIV-exposed noninfected individ-
uals (Langlade-Demoyen et al., 1994; Rowland-Jones et
al., 1995). These characteristics of the nef gene product
are interesting from an immunological perspective and
make it a primary target for HIV vaccine development
(Montagnier, 1995).
A number of approaches to prophylactic and therapeu-
tic vaccination against HIV are currently under evalua-
tion, including the use of viral vectors such as vaccinia
and canary pox, live attenuated viruses, recombinant
proteins, synthetic peptides, naked DNA, and combina-
tions of different antigen delivery systems (Letvin, 1998).
A novel approach to boost immunity in infected persons
depends on controlled interruptions of highly active an-
tiretroviral therapy (Ortiz et al., 1999).
In this report, we used the HLA-A2 transgenic mouse
model to study the Nef-specific HLA-A2-restricted CTL
response to an experimental HIV-1 Nef-expressing DNA
construct. Ten 9-mer peptide fragments from the Nef
protein were selected as possible epitopes based on
predicted binding to the HLA-A2 molecule by a com-
puter-driven algorithm. Binding was confirmed using an
HLA-A2 stabilization assay. We detected specific and
HLA-A2-restricted CTL responses to three of the pep-
tides 2 weeks after immunization with the Nef-express-
ing DNA-vaccine and demonstrated that three peptides
generate CTL responses after peptide immunization.
One epitope maps in a region of the protein where no
epitopes have been described previously. In addition, we
observed and quantified T cell proliferative responses in
immunized mice. Our data have implications for the de-
TABLE 1
Search for HLA-A2 Binding Peptides in the HIV-1 Nef Protein
Ranka Position Sequence Scorea
1 85–93 AALDLSHFL 24.7
2 183–191 LEWRFDSRL 22.2
3 174–182 GMDDPEREV 16.5
4 108–116 RQDILDLWV 15.5
5 111–119 ILDLWVYHT 11.7
6 139–147 LTFGWCFKL 10.8
7 44–52 ALTSSNTAA 5.0
8 68–76 VGFPVKPQV 2.9
9 52–60 ATNADCAWL 1.6
10 81–89 MTYKAALDL 1.6
Control Gag 77–85 SLYNTVATL 157.2
a Scan of the Nef protein sequence for putative HLA-A2 binding
eptides was performed using a search engine at the web site: http://
ww-bimas.dcrt.nih.gov/molbio/hla_bind/index.html. Analysis is based
n coefficient tables deduced from the published literature by Dr.
enneth Parker. Score indicates estimated half-time of dissociation.velopment of a therapeutic DNA vaccine against HIV
(Calarota et al., 1999).RESULTS
Identification of HIV-1 Nef-derived HLA-A2
binding peptides
In the search for putative HLA-A2 binding peptide
sequences in the HIV-1 Nef HXB3 sequence, we used a
search algorithm based on individual amino acid binding
coefficients described by Parker et al. (1994). The ten
-mer peptide sequences predicted by this method to
ave the longest half-time of dissociation in complex
ith HLA-A2 are shown in Table 1. The well-character-
zed HIV-1 Gag 77-85 epitope was included as a positive
ontrol (Tsomides et al., 1994). Next, a T2 HLA stabiliza-
ion assay was performed to confirm the binding prop-
rties of these peptides (Fig. 1). This assay is based on
he accumulation of “empty” MHC class I molecules at
he surface of TAP1/TAP2-deficient T2 cells cultured at
6°C, when they are stabilized by the addition of specific
xtracellular peptides (Ljunggren et al., 1990; Stuber et
l., 1992). Overall, the result of the T2 stabilization assay
as in agreement with that of the computer-driven algo-
ithm, in that predicted good binders were generally
etter at stabilizing HLA-A2 on the cell surface. Four
ef-derived peptides, at positions 85-93, 108-116, 111-
19, and 139-147, bound as efficiently as the control Gag
7-85 sequence (Fig. 1). Two peptides, the 44-52 and the
1-89, stabilized HLA-A2 weakly (Fig. 1). However, two
eptides predicted to bind, the Nef 183-191 and 174-182
eptides, were not able to stabilize HLA-A2 (Fig. 1).
hese data demonstrate the presence of Nef-derived
eptide fragments, which bind and stabilize the HLA-A2
estriction element.
FIG. 1. HLA-A2 binding capacity among Nef-derived peptides. Nine-
mer peptides were tested for HLA-A2 binding by using the T2 MHC
class I stabilization assay. Briefly, T2 cells were incubated with indi-
cated amounts of peptide for 12 h at 26°C, washed, chased at 37°C for
30 min, and analyzed for HLA-A2 expression by FACS using the mAb
HB54. Expression induced in the absence of peptide was subtracted
from all values. Nef-derived peptides were as indicated in the legend,






































114 SANDBERG ET AL.CTL responses against HLA-A2 binding Nef peptides
in DNA-immunized mice
We next investigated whether HLA-A2 transgenic mice
immunized epidermally with a single 1-mg dose of nef DNA
evelop CTL responses against any of the HLA-A2 binding
ef peptides. Spleen cells were recovered either 2 or 4
eeks after immunization and restimulated with peptides
or 6 days. CTL responses were detected against several
eptides 2 weeks after immunization (Fig. 2). The Nef 44-52
nd 81-89 peptides were efficiently targeted, and the 85-93
equence was somewhat less efficiently recognized. The
74-182 peptide was weakly recognized in one experiment
nly. It is notable that the 44-52 and 81-89 peptides are the
rimary targets of the CTL response, despite not being
mong the best HLA-A2 binding peptides. No or very weak
esponses were detected against the 183-191, 108-116, 111-
19, 139-147, 68-76, and 52–60 peptides. No CTL activity
as detected in two of two experiments 4 weeks after
mmunization, indicating that CTL responses were short-
ived (data not shown). Taken together, these data show
FIG. 2. Epitope-specific CTL derived from HIV-1 nef DNA-immunized
peptide was assayed against Con A blasts from HLA-A2 transgenic m
positive experiments of a total of three experiments.hat a single DNA immunization elicits CTL responses
gainst three of the HLA-A2 binding Nef peptides. Further- tore, the selection of CTL epitopes in Nef does not corre-
ate with HLA-A2 binding capacity.
LA-A2 restricted CTL responses against Nef
eptides in peptide-immunized mice
We next examined the potential usefulness of the Nef-
erived peptides for peptide immunization. Two of the pep-
ides recognized after DNA immunization, the 44-52 and
5-93 peptides, and one that was not recognized despite
eing a good HLA-A2 binder, the 139-147, were dissolved in
djuvant and individually injected subcutaneously into
LA-A2 transgenic mice. These three peptides all gener-
ted peptide-specific CTL responses (Fig. 3). CTL re-
ponses were clearly restricted by the transgenic human
LA-A2 molecule, because preincubation with specific
eptide sensitized T2 target cells but not RMA-S cells for
ysis. Thus the Nef-derived peptides elicit peptide-specific
nd HLA-A2-restricted CTLs when injected in adjuvant.
-cell proliferation against the whole Nef protein and
gainst 20-mer peptides
transgenic mice. CTL activity after 6 days of in vitro restimulation with
lsed (F) or not pulsed (E) with specific peptide. Shown is one of twoHLA-A2We next measured T-cell proliferation in splenocytes
o whole Nef protein and 20-mer peptides 2 and 4 weeks
2-posi
w ative e
115HIV-1 NEF T-CELL RESPONSES IN HLA-A2 TRANSGENIC MICEafter nef DNA immunization. Strong proliferation was
observed against recombinant Nef protein after 2 weeks,
whereas proliferation was relatively weak 4 weeks after
immunization (Fig. 4). Responses primarily focused on
the 106-125, 166-185, and 181-205 peptides (Fig. 4). Some
proliferation was also observed to the 16-35 peptide and
to the peptides spanning positions 121–170 of the pro-
tein. Similar to the response detected to whole Nef pro-
tein, these peptide-specific proliferative responses
quickly decreased, and only weak proliferation was ob-
served 4 weeks postimmunization (Fig. 4). These data
FIG. 3. HIV-1 Nef peptide-specific CTL generated by peptide immu
measured after 6 days of in vitro restimulation with peptide. The HLA-A
as included as an HLA-A2 negative control. Shown is one represent
FIG. 4. T cell proliferation after HIV-1 nef DNA immunization. Prolife
protein and 20-mer synthetic peptides 2 weeks (filled columns) and 4 weeks (
of data from four experiments.demonstrate that nef DNA immunization elicits helper
T-cell responses to several epitopes in HLA-A2 trans-
genic mice.
DISCUSSION
HLA-A2 transgenic mice have been used to evaluate
CTL responses against human pathogens, including
hepatitis B and C virus (Sarobe et al., 1998; Wentworth et
al., 1996), influenza virus (Vitiello et al., 1991), human
papilloma virus (Wentworth et al., 1996), and recombinant
. CTL activity from peptide-immunized HLA-A2 transgenic mice was
tive cell line T2 was used as target cell. The mouse RMA-S target cell
xperiment of three experiments.
responses in immune splenocytes in vitro to whole recombinant Nefnizationrative
open columns) after immunization. Shown is mean and standard error
(
e
116 SANDBERG ET AL.vaccinia constructs (Woodberry et al., 1999). Immunoge-
nicity in this mouse model has been shown to correlate
well, although not completely, with antigenicity for human
CTL (Man et al., 1995; Wentworth et al., 1996). Here, we
describe the use of HLA-A2 transgenic mice in the eval-
uation of the T-cell response to an HIV-1 nef DNA con-
struct. CTL responses were observed against several
epitopes, identified as putative HLA-A2-presented pep-
tides by a computer-driven algorithm followed by assess-
ment by an HLA-A2 stabilization assay. Helper T-cell
proliferation was observed to whole Nef protein and
several 20-mer peptides.
The Nef peptides exhibiting the best binding to
HLA-A2 were not the ones preferentially recognized in
the CTL response to nef DNA vaccination. On the con-
trary, the strongest CTL activity was directed against the
44-52 and 81-89 peptides, both of which were compara-
bly poor at stabilizing HLA-A2. Most interestingly, the
44-52 epitope resides outside the regions of Nef where
previously described CTL epitopes are clustered. This is
important because it is highly desirable to target several
independent epitopes in a vaccine-induced CTL re-
sponse. A previous study indicated that a 15-mer peptide
of the Nef LAI sequence, which included the correspond-
ing amino acids 44–52, could bind HLA-A2 (Choppin et
al., 1991). Among the strongly binding peptides, only
85-93 was targeted. Peptides including or overlapping
with the 85-93 peptide have previously been described
as CTL epitopes restricted by HLA-A3 (McMichael and
Walker, 1994) and HLA-A11 (Culmann et al., 1991).
It is tempting to speculate that the evolutionary selec-
tion pressure exerted by CTL responses has selected
against good binding of immunogenic Nef peptide frag-
ments to common MHC class I alleles, as was observed
recently in macaques (Evans et al., 1999). In some sup-
port of this, we observed that the replacement of amino
acid positions 3 and 7 in the 85-93 for phenylalanines,
which commonly occur naturally, leads to significantly
increased predicted binding to HLA-A2 (data not shown).
Also, the strongly binding peptides not targeted by CTLs
(e.g., 108-116) may not be efficiently processed and thus
not presented at the surface of antigen-presenting cells.
No or only very weak CTLs were detected against the
108-116, 111-119, and 139-147 peptides after DNA immu-
nization despite their capacity to efficiently stabilize A2.
The absence of CTL responses against these peptides
may be due to low intrinsic immunogenicity. Our obser-
vation that the 139-147 peptide induced a strong CTL
response on immunization in adjuvant speaks against
this possibility. Also, CTL recognition of a peptide corre-
sponding to a 1-amino-acid residue longer variant of the
139-147 peptide (i.e., the 138-147) has been described in
the human CTL response against HIV (Durali et al., 1998;
Haas et al., 1996; Wilson et al., 1999). This discrepancy
between the human and mouse HLA-A2-restricted CTL
responses may be due to differences in antigen process-ing (Braud et al., 1998). Similarly, we observed no CTLs
against the 183-191 peptide, despite the finding that the
corresponding 10-mer can be targeted by the human
response (Haas et al., 1996). However, this may be due to
the fact that the 9-mer variant apparently does not bind to
the HLA-A2 molecule (Fig. 1).
Controversy exists concerning the HLA-A2 restriction
of the Nef 190-198 CTL epitope (Brander et al., 1998;
Connan et al., 1994; Hadida et al., 1995; Hunziker et al.,
1998). Because the corresponding peptide in the HXB3
Nef sequence scored very low in the computer-based
predicted binding and no binding was observed in the T2
stabilization assay (Hunziker et al., 1998), we did not
include this peptide in our experiments.
In summary, we have identified several HIV-1 Nef
epitopes presented by HLA-A2 in mice transgenic for this
human MHC class I molecule. This approach of identi-
fying human CTL epitopes seems promising, although
the relevance of these epitopes for the human immune
response must be confirmed. Our results further confirm
the usefulness of computerized predictions of the
strength of MHC–peptide interactions in combination




T2 is a hybrid between the two human cell lines 0.174
and CEM, and it has an antigen processing deficiency
due to a deletion in the MHC class II region that includes
the TAP1 and TAP2 genes. RMA-S is a TAP2-deficient
variant of the Rauscher virus-induced B6 lymphoma RMA
(Ljunggren and Karre, 1985). Cell lines were maintained
at 37°C and 5% CO2 in RPMI 1640 tissue culture medium
supplemented with 5% FCS, 50 mg/ml streptomycin, 100
mg/ml penicillin, and 2 mM L-glutamine. Concanavalin A
Con A)-activated blasts were generated by culturing
rythrocyte-depleted splenocytes in 5 mg/ml Con A for 2
days in tissue culture medium as described above with
10% FCS.
Synthetic peptides
Synthetic peptides corresponding to HIV-1 Nef (HXB3) pro-
tein sequence positions 44-52 (ALTSSNTAA), 52-60
(ATNADCAWL), 68-76 (VGFPVKPQV), 81-89 (MTYKAALDL),
85-93 (AALDLSHFL), 108-116 (RQDILDLWV), 111-119
(ILDLWVYHT), 139-147 (LTFGWCFKL), 174-182 (GMDDPEREV),
and 183-191 (LEWRFDSRL) and the HIV-1 Gag protein position
77-85 (SLYNTVATL) (Tsomides et al., 1994) were used for CTL
experiments. For the stimulation of T helper cell activity in
proliferation assays, 20 mers with 5-amino-acid overlap cov-
ering the complete Nef protein were used. Peptides were
























117HIV-1 NEF T-CELL RESPONSES IN HLA-A2 TRANSGENIC MICEMice and immunizations
Mice transgenic for the chimeric MHC class I mol-
ecule composed of a1/a2 from HLA-A2 and a3 from
-2Kb on C57Bl/6 background (Vitiello et al., 1991)
ere bred at the Microbiology and Tumor Biology
enter of the Karolinska Institutet. Animal care was in
ccordance with institutional guidelines, and mice
ere used at an age of 6–12 weeks. The plasmid used
or DNA vaccination contained the HIV-1 nef gene from
he HXB3 strain under the control of the human cyto-
egalovirus (CMV) immediate-early promoter, as de-
cribed by Hinkula et al. (1997). Plasmid (1 mg) was
delivered in the abdominal skin by the helium pulse
Accell device (courtesy of J. Haynes, Auragen, Madi-
son, WI) coated onto 0.95-mm gold particles (Aldrich
Chemical, Milwaukee, WI) (Haynes et al., 1994). Con-
trol animals were given empty plasmid vector and/or
PBS. To elicit CTLs by peptide immunization (Sand-
berg et al., 1998), 100 mg peptide was dissolved in
distilled water and mixed with incomplete Freund’s
adjuvant in a 1:1 ratio by sonication and injected
subcutaneously in the base of the tail. At 12 days after
peptide immunization and 2 or 4 weeks after DNA
immunization, 25 3 106 immune splenocytes were
ocultured with 25 3 106 2000-rad-irradiated spleno-
cytes in the presence of 0.1 mM peptide in 12 ml
omplete medium (RPMI 1640 supplemented with 10%
CS, 0.1 mM nonessential amino acids, 1 mM sodium
yruvate, 5 3 1025 M 2-mercaptoethanol, 2 mM L-
glutamine, and 50 mg/ml streptomycin/100 mg/ml pen-
icillin) at 37°C and 5% CO2. Splenocytes from four
NA-immunized mice were pooled and then split into
eparate cultures during in vitro culture with peptide.
ix days later, these cells were used as effector cells
n a 51Cr-release assay.
HLA-A2 peptide binding assays
Initial scan of the HXB3 Nef protein sequence for
putative HLA-A2 binding peptides was performed using
a search engine at the Web site http://www-bimas.
dcrt.nih.gov/molbio/hla_bind/index.html. The analysis is
based on coefficient tables deduced from the published
literature by Dr. Kenneth Parker (Parker et al., 1994). The
peptide stabilization assay was used to test candidate
binders for real HLA-A2 binding (Ljunggren et al., 1990;
Stuber et al., 1992). T2 cells were incubated overnight at
26°C in complete medium with titrated concentrations of
peptide, followed by washing and a 40-min chase at
37°C. Cells were then incubated with HB54 mouse mAb
specific for HLA-A2 for 30 min on ice, washed, and
stained with goat anti-mouse FITC conjugate (PharMin-
gen, San Diego, CA) on ice for 30 min. After washing,
analysis was performed using an FACScan (Becton Dick-
inson, Sunnyvale, CA) using Cellquest software.Proliferation assay
Spleen cells (2 3 105 cells/well) were cultured for 5–6
ays in RPMI 1640 supplemented with 2 mM L-glutamine,
100 mg/ml penicillin/50 mg/ml streptomycin, and 10%
etal calf serum in the presence of 1 mg/ml whole antigen
r 5 mg/ml peptide. Then 50 ml/well 3H1-labeled thymi-
dine (1 mCi) was added, and cells were incubated for
16 h before cells were harvested and thymidine incorpo-
ration was measured using a b-counter. Stimulation in-
dex (SI) was calculated by dividing the mean cpm values
in triplicate antigen-stimulated wells with the mean cpm
of medium control wells.
CTL assay
CTL activity was measured in a standard 51Cr-release
ssay. Briefly, peptide coated T2, RMA-S, or Con A blast
arget cells were prepared by incubating cells with 10
mM peptide for 1 h at 37°C. Coated cells were labeled
with 10 ml of 10 mCi/ml 51Cr for 1 h at 37°C. Titrated
numbers of effector cells were incubated with 3 3 103 of
51Cr-labeled target cells for 4 h at 37°C and 5% CO2. After
incubation, released radioactivity was measured and
specific lysis was calculated according to the formula:
specific release (%) 5 [(experimental release 2 sponta-
neous release)/(maximum release 2 spontaneous re-
lease)] 3 100.
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